Daratumumab, Ixazomib, Dexamethasone
ΕΑΕ-2018/ΜΜ03
Phase 2 small_molecule active
Quick answer
Daratumumab, Ixazomib, Dexamethasone for Multiple Myeloma is a Phase 2 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Multiple Myeloma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active